<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806986</url>
  </required_header>
  <id_info>
    <org_study_id>GTI1503</org_study_id>
    <nct_id>NCT02806986</nct_id>
  </id_info>
  <brief_title>Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency</brief_title>
  <official_title>A Multi-Center, Open-Label, Single-Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects
      and 20 pediatric subjects treated with subcutaneously administered IGSC 20% who complete the
      entire study. This study will include 3 study stages: Screening/Previous Regimen Phase, IGSC
      20% Treatment Stage 1 (13 IGSC 20% weekly doses), and IGSC 20% Treatment Stage 2 (39 IGSC 20%
      weekly doses). A total of 52 doses of IGSC 20% will be administered with a final follow-up
      visit 1 week after the last dose at Week 53. Subjects/caregivers will be trained on
      self-administration of IGSC 20% by the clinical site personnel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, open-label, single-arm, efficacy, PK, safety and
      tolerability study of IGSC 20% in subjects with PI. Approximately 60 subjects will be
      enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated
      with subcutaneously administered IGSC 20% who complete the entire study.

      This study will include 3 study stages: Screening/Previous Regimen Phase, IGSC 20% Treatment
      Stage 1 (13 IGSC 20% weekly doses), and IGSC 20% Treatment Stage 2 (39 IGSC 20% weekly
      doses).

      Previous Regimen Phase: Subjects will be infused with their current ongoing (&quot;previous
      regimen&quot;) IVIG/SCIG regimen (pIV/pSC) in the clinic to obtain 2 trough IgG levels (obtained
      prior to each pIV/pSC infusion) on each subject's &quot;previous regimen&quot;.

      20% IGSC Treatment Stage 1: The first dose of IGSC 20% will be administered at the clinical
      site immediately after Baseline assessments are complete (SC#1). All subjects will receive 13
      IGSC 20% infusions at weekly intervals. IgG trough blood levels will be measured at all
      (except SC#3) study visits All other doses of IGSC 20% may be infused at home (once properly
      trained) or in the clinic. The Treatment Stage 1 dose will continue into IGSC 20% Treatment
      Stage 2.

      IGSC 20% Treatment Stage 2: The IGSC 20% dose (mg/kg) will remain constant with no dose
      adjustment permitted in this phase, unless it is absolutely medically necessary. While all
      subjects will have a SC#17 clinic visit and standard assessments, serial PK sampling will
      only be performed in a subset of adult subjects:
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious bacterial infections in one year</measure>
    <time_frame>Baseline to Week 53</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough (pre-dose) concentration of total IgG</measure>
    <time_frame>Pre-dose at 2 time points during the Screening/Previous Regimen Phase and Baseline and pre-dose at Weeks 2 through 52 during IGSC 20% Treatment Stages 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection of any kind</measure>
    <time_frame>Baseline to Week 53</time_frame>
    <description>Includes serious and nonserious infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on any antibiotic</measure>
    <time_frame>Baseline through Week 53</time_frame>
    <description>Includes oral, parenteral, oral plus parenteral, prophylactic, and therapeutic antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations due to infection</measure>
    <time_frame>Baseline through Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of activities missed per subject year</measure>
    <time_frame>Baseline through Week 53</time_frame>
    <description>Includes work, school, and daily activities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>IGSC 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IGSC 20%</intervention_name>
    <description>Weekly administration of IGSC 20% via intravenous infusion</description>
    <arm_group_label>IGSC 20%</arm_group_label>
    <other_name>Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring IgG
             replacement therapy

          -  No serious bacterial infection within the 3 months prior to Screening and has no SBIs
             up to the time of the Baseline Visit

          -  Currently on IgG replacement therapy (stable regimen [dose and dosing interval] via IV
             or SC infusion) for ≥ 3 consecutive months at a dosage of at least 200 mg/kg per
             infusion

          -  Documented (within previous 3 months) of an IgG trough level of ≥ 500 mg/dL on current
             IgG replacement therapy regimen

          -  Screening/pre-Baseline trough IgG levels must be ≥ 500 mg/dL.

        Exclusion Criteria:

          -  Known serious adverse reaction to immunoglobulin or any severe anaphylactic reaction
             to blood or any blood-derived product

          -  History of blistering skin disease, clinically significant thrombocytopenia, bleeding
             disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy
             would be contraindicated during the study

          -  Isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or
             transient hypogammaglobulinemia of infancy

          -  Nephrotic syndrome, and/or a history of acute renal failure, and/or severe renal
             impairment, and/or is on dialysis

          -  Known previous infection with or clinical signs and symptoms consistent with current
             hepatitis B virus or hepatitis C virus infection

          -  History of (year prior to Screening or 2 episodes in lifetime) or current diagnosis of
             deep venous thrombosis or thromboembolism (e.g., myocardial infarction,
             cerebrovascular accident, or transient ischemic attack)

          -  Acquired medical condition known to cause secondary immune deficiency, such as chronic
             lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia
             (absolute neutrophil count less than 1000/μL [1.0 x 10^9/L]), or human
             immunodeficiency virus infection/acquired immune deficiency syndrome

          -  HIV positive by nucleic acid amplification technology based on a Screening blood
             sample

          -  Uncontrolled arterial hypertension (adult subjects: systolic blood pressure &gt; 160 mmHg
             and/or diastolic blood pressure &gt; 100 mmHg)

          -  Receiving any of the following medications: (a) immunosuppressants including
             chemotherapeutic agents, (b) immunomodulators, (c) long-term systemic corticosteroids
             defined as daily dose &gt; 1 mg of prednisone equivalent/kg/day for &gt; 30 days Note:
             Intermittent courses of corticosteroids of not more than 10 days would not exclude a
             subject. Inhaled or topical corticosteroids are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ed Corsi</last_name>
    <phone>919-316-6222</phone>
    <email>Ed.Corsi@grifols.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masaryk University</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mother-Child Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Haut Leveque Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg - Hospital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Professor Hess Children's Hospital</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Municipal Hospital St. Georg</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Sankt Augustin</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki im. dr. Antoniego Jurasza</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Memorial Health Institute</name>
      <address>
        <city>Warsaw</city>
        <zip>4736</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Ari I Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen Silvia Children´s Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stockholm</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wal</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Frimley Health NHS Trust</name>
      <address>
        <city>Camberley</city>
        <zip>GU167UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

